Can you get tirzepatide in the EU, and in what forms?

The short answer

Tirzepatide is available across the EU as Mounjaro — a single EMA-approved brand covering both type 2 diabetes and weight management, by prescription only. Unlike semaglutide there's no oral version and (yet) no separate weight-loss brand name; it's all Mounjaro. The barriers are the same as the rest of the class: eligibility, cost and reimbursement by country, and supply shortages — not legality.

Evidence tier: 2 — based on the EMA marketing authorization and pivotal trials. Access and supply notes are practical and vary by member state. This is education, not medical or legal advice.

The key points:

• One EMA-approved brand: Mounjaro — covers both diabetes and weight management
• Prescription only — no legitimate OTC or research route; no oral form
• Injectable, once weekly — the highest-efficacy GLP-1 currently approved
• Barriers are cost, eligibility, and shortages — not legality

This is part of our EU availability cluster — see the EU peptide availability overview and the full tirzepatide deep dive.

Is tirzepatide legal and available in the EU?

Evidence tier: 1–2 — EMA marketing authorization.

Yes. Tirzepatide is authorized centrally by the EMA under the brand Mounjaro, which received EU marketing authorization in September 2022 (EMA: Mounjaro). A useful simplification for EU patients: where the US splits tirzepatide into two brands (Mounjaro for diabetes, Zepbound for obesity), the EU uses the single Mounjaro name for both the type 2 diabetes and the weight-management uses. So there's one product to ask about, prescribed according to your indication.

Like the rest of the GLP-1 class, Mounjaro is a prescription-only medicine. There is no legitimate over-the-counter or "research-use" route in the EU, and the gray-market channels used for unapproved peptides are neither necessary nor safe for a drug that's properly available through a prescriber. The contrast with unapproved compounds like BPC-157 (covered in the EU availability overview) is the same as for semaglutide: the question isn't legality, it's eligibility and supply.

Injectable only — is there an oral or alternative form?

Evidence tier: 2 — based on approved formulations.

Tirzepatide in the EU is injectable only — a once-weekly subcutaneous pen. There is no oral tirzepatide (the only oral GLP-1 on the market is semaglutide's Rybelsus, covered in our semaglutide EU guide). So if an oral option is a hard requirement, tirzepatide isn't it today, though oral incretin pipelines are advancing across the industry.

What tirzepatide offers in return is efficacy: it's the highest-performing approved GLP-1 on weight, around 20%+ average in SURMOUNT-1 (Jastreboff 2022), and it beat semaglutide head-to-head (SURMOUNT-5, Aronne 2025). For an EU patient choosing between the two approved options, the trade-off is roughly "tirzepatide for maximal weight effect, injectable-only" versus "semaglutide for the longer track record, proven cardiovascular outcomes, and an oral tablet." That clinical comparison sits on top of the practical one — what's reimbursed and in stock where you are. The mechanism and side-effect detail is in the tirzepatide deep dive.

What makes it hard to get in practice?

Evidence tier: 2–3 — access-system observation, varies by country.

The barriers mirror semaglutide's, and again none is about legality. Eligibility: weight-management prescribing usually requires meeting BMI or comorbidity thresholds, and access is often gated more tightly for weight than for diabetes. Cost and reimbursement: in many member states the weight-management use is largely private-pay, and reimbursement varies widely between countries, so the real obstacle is frequently financial. Shortages: as a newer, in-demand GLP-1, Mounjaro has been caught in the same EU-wide supply pressure the EMA has been managing across the class (EMA on GLP-1 shortages), so availability of specific dose strengths can fluctuate.

Because tirzepatide is newer to the EU than semaglutide, some patients also find prescriber familiarity and formulary placement still catching up in certain systems. As with the rest of the class, the EU's lack of a US-style telehealth-and-compounding pipeline means there's no frictionless back-channel — the route is a prescriber and a pharmacy. That's a feature for safety even if it's a friction for speed.

It's also worth flagging the compounding contrast directly, because it's the source of a lot of cross-border confusion. In the US, "compounded tirzepatide" became widely marketed during shortages; in the EU, large-scale compounding of an approved, patented drug like this is not a generally available legal route, so the equivalent product mostly doesn't exist through legitimate channels. EU patients who read about cheap compounded tirzepatide online are usually looking at a US-specific (and now FDA-restricted) phenomenon or at outright gray-market sellers — neither of which is a safe or legal EU shortcut. The honest framing is that the approved Mounjaro route is the one with quality assurance, and the apparent "alternatives" trade that assurance away.

Mounjaro at the EU pharmacy: what to expect

Evidence tier: 2–3 — practical access observation, varies by country.

Knowing it's "available" doesn't tell you what the process feels like, so here's the practical shape. Mounjaro is dispensed as a once-weekly pen (or vial in some markets), in a titration ladder of increasing doses — you start low and step up over weeks to manage GI side effects, so your first prescription won't be the maintenance dose. Expect your prescriber to gate the weight-management indication behind eligibility criteria (BMI thresholds, sometimes documented prior attempts), and expect the cost question to loom large: in many member states weight-management Mounjaro is private-pay, so the monthly out-of-pocket cost, not a law, is often the real decider.

Supply adds a wrinkle. Because Mounjaro is newer and in heavy demand, specific dose strengths can be intermittently unavailable, and pharmacies may not stock every step of the titration ladder at all times — so continuity can require some planning with your prescriber and pharmacy. None of this is unique to tirzepatide; it's the shared reality of the in-demand GLP-1 class in the EU right now. The reassuring part is that what you ultimately collect is the genuine, EMA-regulated product with known dosing and quality — the thing the gray market cannot offer. If you're weighing it against semaglutide, our semaglutide EU guide lays out that side, and the clinical comparison lives in the two deep dives.

Should you buy tirzepatide outside a pharmacy in the EU?

Evidence tier: 2–3 — risk reasoning; not legal advice.

No. Tirzepatide is legitimately available by prescription, so gray-market or "research" tirzepatide offers no real advantage and meaningful risk — it's unapproved, unregulated for purity, potentially counterfeit or mis-dosed, and injecting a product of unknown origin carries the contamination concerns set out in our independent lab-testing guide. Compounded tirzepatide, prominent in the US, is far more constrained in the EU, and sourcing the raw drug yourself is not a safe substitute for a prescription.

If cost or eligibility is the barrier, the constructive path is a discussion with a GP or a diabetes/weight-management service about whether you qualify and what's covered, not the gray market. The honest EU framing is identical to semaglutide's: tirzepatide is the good case — a real, regulated, best-in-class medicine you can obtain properly — and the effort of going through a prescriber beats trading a solvable access problem for an unsolvable safety one.

There's one tirzepatide-specific wrinkle worth knowing. Because the EU uses a single brand (Mounjaro) for both diabetes and weight management, there isn't the Ozempic/Wegovy-style brand split that sometimes drives off-label brand-switching during shortages — which simplifies things, but also means a Mounjaro shortage hits both patient groups at once. If supply of your dose strength is interrupted, the right response is to coordinate with your prescriber on whether to hold at a lower step, switch within the class, or wait, rather than to seek the drug through unofficial channels. The same logic that makes tirzepatide attractive — it's a potent, regulated medicine — is exactly why a momentary supply gap is worth handling clinically instead of risking an unverified substitute.

Limitations

This is educational content, not medical or legal advice.

• Rules, reimbursement, and eligibility vary by EU member state — this is a general overview.
• Approval status and indications change — verify current EMA status and local rules.
• Tirzepatide is injectable-only in the EU — no oral form exists today.
• Supply fluctuates — Mounjaro can be hard to fill during shortages.
• Gray-market tirzepatide is unapproved and unsafe — a prescription is the only sound route.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Tirzepatide is available across the EU as Mounjaro — one EMA-approved brand for both diabetes and weight management, prescription only, injectable only, authorized since September 2022. It's the highest-efficacy approved GLP-1, but there's no oral version (that's semaglutide's Rybelsus). The obstacles are eligibility, cost and patchy reimbursement, and shortages — access frictions, not legal ones — so the right route is a prescriber, never the gray market.

Related on this site

• EU peptide availability: the overview
• Tirzepatide deep dive (2026)
• Semaglutide in the EU (Ozempic, Wegovy, Rybelsus)
• Retatrutide in the EU: pipeline status
• GLP-1 complete guide (2026)
• Tirzepatide peptide page
• Our evidence-tier framework

References

• European Medicines Agency. Mounjaro (tirzepatide) — EPAR / medicine overview. EMA: Mounjaro — EU authorization for diabetes and weight management (Sep 2022).
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 — pivotal efficacy.
• Aronne LJ, et al. 2025. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. PMID 40353578 — head-to-head superiority.
• European Medicines Agency. EU actions to tackle shortages of GLP-1 receptor agonists. EMA news — supply/access context.